NCT00779922

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: Poitiers University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population. and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.

Conditions

• Multiple Myeloma
• Impaired Renal Function

Interventions

Type	Name	Description
DRUG	lenalidomide

Timeline

• Start date: 2008-11-01
• Primary completion: 2012-09-01
• First posted: 2008-10-24
• Last updated: 2016-10-11

Locations

1 site across 1 country: France